ALFA Finder| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 81.4 | 80.7 | 56.2 |
| Other income | -0.8 | -1.0 | 1.6 |
| Total income | 80.5 | 79.7 | 57.8 |
| Profit before exceptional items & tax | 2.0 | 2.1 | 1.4 |
| Profit before tax | 2.0 | 2.1 | 1.4 |
| Net profit | 1.2 | 1.3 | 0.2 |
| Operating margin | 2.5% | 2.6% | 2.4% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +500.00% |
|---|---|
| Net profit, quarter on quarter | -7.70% |
| Revenue, year on year | +44.80% |
| Operating profit, year on year | +1500.00% |
| Operating profit, quarter on quarter | -9.70% |
NSE results filing, NSE: BALAXI. Figures extracted from the filing.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹23.35
- Market cap
- ₹128.9 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 53.2×Sector 43.8×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals filed its RTA report for October 2026 on re-lodgement of physical share transfers. All request counts for the month are NIL.
Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals reported nil activity regarding the re-lodgement of physical share transfer requests for August 2026. This is a routine regulatory compliance filing.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.